ArticleJournal of acquired immune deficiency syndromes (1999)2011
Optimal time on HAART for prevention of mother-to-child transmission of HIV.
Article in Journal of acquired immune deficiency syndromes (1999), 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT02459678 (ART Readiness in HIV-infected Pregnant Women), which is not on this map. Cited by 43 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
ART Readiness in HIV-infected Pregnant Women: From Formative Qualitative Research to Individual Randomized Trial
Who cites it
43 citing papers in PubMed, 1 synthesis or guideline pooled it, 76 citations in OpenAlex.
- Integrating antiretroviral therapy into antenatal care and maternal and child health settings: a systematic review and meta-analysis.Bulletin of the World Health Organization · 2013Pooled it
- Pooled individual data analysis of 5 randomized trials of infant nevirapine prophylaxis to prevent breast-milk HIV-1 transmission.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2013Trial
- Predictive factors of plasma HIV suppression during pregnancy: a prospective cohort study in Benin.PloS one · 2013Trial
- Effects of valacyclovir on markers of disease progression in postpartum women co-infected with HIV-1 and herpes simplex virus-2.PloS one · 2012Trial
- Prevention of mother-to-child transmission of HIV in the MENA region: A systematic review with comparative evidence from Sub-Saharan Africa.Infectious medicine · 2026Review
- Timing of maternal antiretroviral therapy initiation and HIV status of children at 18 months in Ibadan, Nigeria.BMC infectious diseases · 2026Article
- The progress of mother-to-child transmission of Human Immunodeficiency Virus (HIV) after Dolutegravir (DTG) optimization program: evidence from a multicenter cohort study in Ethiopia.BMC public health · 2024Article
- Residual transmission of HIV infection from mother to child in the Atlantic and littoral departments in Benin.BMC pediatrics · 2024Article
- Reduced mother-to-child transmission rates of HIV between 2017 and 2020 in Kenya. What changed?Journal of public health in Africa · 2024Article
- Patterns of engagement in HIV care during pregnancy and breastfeeding: findings from a cohort study in North-Eastern South Africa.BMC public health · 2021Article
- Viral suppression and factors associated with failure to achieve viral suppression among pregnant women in South Africa.AIDS (London, England) · 2020Article
- Initiation of antiretroviral therapy or antiretroviral prophylaxis in pregnant women living with HIV registered in five townships of Mandalay, Myanmar: A cross sectional study.BMC pregnancy and childbirth · 2019Article
- Uptake of antiretroviral therapy in HIV-positive women ever enrolled into 'prevention of mother to child transmission' programme, Mandalay, Myanmar-a cohort study.BMC pregnancy and childbirth · 2018Article
- Same-day antiretroviral therapy (ART) initiation in pregnancy is not associated with viral suppression or engagement in care: A cohort study.Journal of the International AIDS Society · 2018Article
- Article
- Underutilisation of routinely collected data in the HIV programme in Zambia: a review of quantitatively analysed peer-reviewed articles.Health research policy and systems · 2017Review
- Option B+ for prevention of vertical HIV transmission has no influence on adverse birth outcomes in a cross-sectional cohort in Western Uganda.BMC pregnancy and childbirth · 2017Observational
- Low mother-to-child HIV transmission rate but high loss-to-follow-up among mothers and babies in Mandalay, Myanmar; a cohort study.PloS one · 2017Article
- Perspectives on safer conception practices and preconception counseling among women living with HIV.Health care for women international · 2016Article
- Detectable Viral Load in Late Pregnancy among Women in the Rwanda Option B+ PMTCT Program: Enrollment Results from the Kabeho Study.PloS one · 2016Observational
Corrections and comments
- Commented on by
- Commented on by
Authors and funding
9 authors at 2 institutions in 2 countries.
Funding
Abstract
objectivesTo determine the impact of time between initiating highly active antiretroviral therapy (HAART) and delivery-duration of antenatal HAART-on perinatal HIV infection.
designWe conducted a retrospective cohort analysis of pregnant HIV-infected women in Lusaka, Zambia. Women in our cohort were receiving HAART and had an infant HIV polymerase chain reaction test between 3 and 12 weeks of life.
methodsWe examined factors associated with infant HIV infection and performed a locally weighted regression analysis to examine the effect of duration of antenatal HAART on perinatal HIV infection.
results: From January 2007 to March 2010, 1813 HIV-infected pregnant women met inclusion criteria. Mean gestational age at first antenatal visit was 21 weeks (SD ± 6), median CD4+ cell count was 231 cells per microliter (interquartile range: 164-329), and median duration of antenatal HAART was 13 weeks (interquartile range 8-19). Fifty-nine (3.3%) infants were HIV infected. Duration of antenatal HAART was the most important predictor of perinatal HIV transmission. Compared with women initiating HAART at least 13 weeks before delivery, women on HAART for ≤4 weeks had a 5.5-fold increased odds of HIV transmission (95% confidence interval: 2.6 to 11.7). Locally weighted regression analysis suggested limited additional prophylactic benefit beyond 13 weeks on antenatal HAART.
conclusionsLow rates of mother-to-child HIV transmission can be achieved within programmatic settings in Africa. Maximal effectiveness of prevention of mother-to-child transmission programs is achieved by initiating HAART at least 13 weeks before delivery.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.